April 28-29, 2021
Online Livestream
Summit
KOL & Thought LeaderEngagement Summit
Identifying and Cultivating Beneficial Long-Term Partnerships with the Most Respected and Influential Opinion Leaders for Each Indication
Days
Hours
Minutes
Seconds

In a time of unprecedented public fear and distrust of institutions, life science companies must be more careful than ever in cultivating KOL relationships that can lend credibility to their products in the minds of the medical community. As regulations grow more strict, and demand for niche products and personalized treatment rises, KOLs are set to play an even more important role in each stage of the drug life cycle.

DGE’s KOL & Thought Leader Engagement Summit is the only conference for life science professionals that focuses specifically on building and getting the most out of these partnerships. Don’t miss out on this unique learning and networking opportunity, presented on a proven interactive streaming platform!

Top Reasons to Attend
  • Gain knowledge from top experts on how to effectively engage with KOLs
  • Identify best strategies to establish and maintain meaningful relationships with KOLs
  • Learn about legal regulations and how to stay in compliance when engaging with KOLs
  • Learn about different approaches and methodologies
  • Examine the different platforms used to identify, track, and map KOLs
Who Should Attend

This livestream conference is designed for life science professionals with the following responsibilities:

  • KOL Management & Engagement
  • Medical Science Liaisons (MSLs)
  • Medical Affairs
  • Opinion/Thought Leader Relations
  • Advisory Boards/Speaker Programs
  • Scientific Communication/Affairs
  • Speaker Programs
  • Commercialization Strategy
  • Brand/Portfolio Management
  • Speaker Bureau Training/Management
  • Field Medical
  • Medical Education
  • External Engagement
  • Advisory Board Service Providers
  • KOL Software Mapping Services
  • KOL Technology Providers
  • Promotional Regulatory Affairs
  • Medical Publications
  • Global Relations
Conference
New Topics
Featured Speakers
Alan Polnariev
ASTRAZENECA
Senior MSL, Nephrology
Alice Chung
GENENTECH
Senior Manager, Strategic Analytics and Intelligence, Medical and Scientific Team
Andrea Schatz-Anderer
81qd
EVP, Strategy & Insights
Anthony Page
VOXX ANALYTICS
CEO
April Kelly
SANOFI GENZYME
Head, Dupixent Thought Leader Liaisons
Brian A. Bohnenkamp
KING & SPALDING LLP
Partner, FDA and Life Sciences Practice
Bryan N. Bischel, PhD
MALLINCKRODT PHARMACEUTICALS
Medical Director, Hepatology
Cherie Hyder
BIOHAVEN PHARMACEUTICALS
Medical Excellence and Operations Lead, Medical Affairs
Christina Tankersley
SANOFI PASTEUR
Senior Director, MSLs
Courtney Zeni
SUNOVION PHARMACEUTICALS
Director, Medical Affairs
Erica Werts
ALIMERA SCIENCES
Senior Director, Medical Affairs, Head Medical Information
Grant Larsen
AEQUUS PHARMACEUTICALS
Chief Commercial Officer
Jane Varian
BEIGENE
Senior Field Medical Director
Jefferson Tea
TAKEDA CANANDA, INC.
VP, Medical and Scientific Affairs
Jeffrey Sears
ASTELLAS PHARMA
Associate Director, Commercial Communications
Jein Song
XERIS
Regional Medical Affairs Director
Jessica Wong
ALUCIO
VP, Product Management & Strategy
Joan Hester
ALIMERA SCIENCES
Director, Medical Affairs
Kasmin Delgado
KYOWA KIRIN
Senior MSL, Associate Director
Kevin Ryan
ACADIA PHARMACEUTICALS
Vice President, Chief Compliance Officer
Laura Jordan
GENENTECH
Senior Thought Leader Liaison
Merideth Rodgers
REGENERON
Director, Medical Affairs
Michael Petro
CYTOKINETICS
Leader, CV Strategy and Thought Leader Liaisons
Michael Zaiac
NOVARTIS
Head of Medical Affairs, Oncology
Naila Inam
AMGEN
Senior Manager, MSL, Hematology-Oncology
Renick Blosser
ALKERMES
Associate Director, Marketing, Thought Leader Engagement
Robert Groebel
MONOCL
VP, Global Medical Strategy
Sunil Mehta
ARGENX
VP, Head, US Medical Affairs
Event Schedule
ALL TIMES ARE IN EST
• Plan for a full product lifecycle by developing a clear and comprehensive KOL management plan
• Recognize the value of the KOL and their contribution in the medical world, while moving away from the transactional mindset
• Maintain continuous engagement and seek feedback
There are a multitude of ways to identify and track KOLs. But before these methods can work for you, you must be prepared to ask specific questions about your overall engagement strategy.
 
• Discover the various methodologies of identifying your KOLs
• Discuss the benefits of different approaches and which should be utilized for your goal
• Understand your business question and which KOLs would best serve you
• Dive into KOL strategic planning and analyze how your company buildsd your thought leader planner
There is a not a one-size-fits-all when it comes to communication. Everyone learns and consumes information differently. It is critical to understand how your KOLs prefer to be engaged.
 
• Invite KOLs to express their opinions on preferred styles
• Be open and flexible with using various media
• Learn how to avoid “info dumping”

Everything we do is intended to impact a treatment eco-system by addressing market needs in some ways. KOLs play many important roles but an essential first step is to fully understand the system, the disease community, in which they operate. This is fundamentally a data challenge. This session will provide practical examples of data-driven engagement including:

  • How data perspectives illuminate actionable insights and opportunities
  • How local ecosystems and KOLs can impact clinical trial accrual and treatment practices
  • How data can find missing patients and identify educational needs
  • How to engage KOLs in the context of all of the above
Cultivating KOL partnerships takes time, dedication and a collaborative mindset. If you proactively plan your engagements and interactions for the year, you can develop genuine relationships that will support your company throughout the product lifecycle.
 
• Identify the best ways to partner with your KOLs based upon your business needs
• Assign team members to serve as key points of contacts for your priority KOLs
• Coordinate internally around congresses and other major activities
• Use new, unique collaborative tools to avoid virtual burnout
• Collect KOL feedback and measure your equity as a company
  • Re-think KOL touchpoints as a KOL-centric journey
  • Leverage scientific exchange efficiently and effectively along the journey
  • Demonstrate impact with unique insights/stories
  • Review practical yet innovative approaches to apply in real life
MSLs can gather important KOL feedback throughout every stage of product development: pre-clinical, clinical, pre-launch, launch, and post-launch. With careful planning, they can have an outsized impact on product performance even before it reaches clinical stages.
 
• Focus on scenario planning to enable long-term agility
• Build relationships with KOLs before product launch to gather feedback about a new product
• Create a united approach for every lifecycle phase

MSLs engage with external stakeholders and are key in developing and building relationships with KOLs. How can you make sure you have the right team members and training at the stage where you need them?

  • Invest in developing competencies of the MSL team
  • Equip MSLs with superior communication skills and a comprehensive understanding of the market situation
  • Train them to be fluent in all relevant digital tools and platforms
ALL TIMES ARE IN EST
COVID only accelerated a pre-existing trend shifting the industry to more virtual meetings and interactions – and there is no going back. Virtual meetings require a different approach in order to encourage interactivity and engage on an intimate, human level.
 
• Define a clear objective for virtual meetings
• Choose advisors who can facilitate the meeting effectively and keep the attendees engaged
• Select an interactive platform that allows maximum engagement and collaboration
KOLs are constantly being contacted by many people from the pharmaceutical industry. It is easy for your communication to be overlooked and get lost. How can you stand out from the crowd?
 
• Send content-driven data that is concise, thought provoking, and brings value to the KOL
• Utilize people who have connections with that KOL for an introduction
• Find new ways to be creative and engaging

An exploration of how Medical affairs organizations continue to further their use of data and analytics in demonstrating value. The availability of novel data sources holds the promise of enhancing strategies and engagement impact. When considering these new sources of knowledge, one must ask, what is the strategic application of healthcare claims via medical affairs?

Discussion Points:

1. Medical Claims and Medical Affairs: Leaders across the (bio)pharmaceutical industry are beginning to see the potential medical claims offer to those driving awareness and understanding of novel approaches to patient care. However, the questions must be asked, how can this data be used effectively and how will it enhance insights into the world’s experts, improving one’s ability to identify, prioritize, and engage differently?

2. Understanding Care Relationships: Understanding how patients are referred is just another foundational piece of information that medical affairs should understand and apply strategically. This evolving dynamic could provide opportunities for a company to improve education, resource deployment, and therapeutic interventions.

3. Comparing Scientific Expertise: Unlike academic research, clinical practice isn’t about developing new innovations or furthering existing knowledge. It’s about the current standard of care and understanding how evidence has impacted decision-making. Identifying clinical leaders provides a new avenue to share emerging evidence to enhance care choices in the future.

An MSL serves as a scientific peer and field-based extension to medical affairs with the purpose of building relationships with KOLs and external HCPs across various therapeutic areas. Understanding the MSL region holistically is vital to alignment of strategic focus for the organization as well as serving the ultimate customer: the patient. This session will introduce the MSL regional map which is a regional planning tool to help identify new KOLs and build depth of knowledge within the MSL’s regional ecosystem. This session will cover two elements of a three-part series on the MSL regional ecosystem roadmap.
 
• Appreciate the breadth of regional focus areas for MSL planning
• Understand the importance of MSL territory planning and novel methods
• Consider how to develop and implement a regional MSL medical plan
• Enhance visibility to questions MSLs should consider to critically evaluate regional sectors and align to medical strategy
Dive into how the industry can improve their engagement strategy.
 
• Share strategies to improve internal communication and collaboration
• Discuss advisory board standards
• Clarify which department should own the relationship
OIG launched a new fraud alert for people who engage with KOLs as promotional speakers and work with them outside of speaker programs. Pharmaceutical and medical device companies have interactions with KOLs and HCPs which clearly state promotional speaking events are vital.
 
• Review OIG Special Fraud Alert
• Recognize OIG skepticism and likely triggers for further investigation
• Discuss how it will affect speaker programs and the industry’s relationship with KOLs
It is critical to stay in compliance when engaging with KOLs; however, some of these rules may seem unclear. Learn from regulatory experts who explain the dos and don’ts of engagement.
 
• Discuss the rules governing MSL activities
• Manage promotion versus education with reports of off-label usage
• Evaluate your interactions with KOLs and how to reduce the risk of breaching compliance
Pharmaceutical companies rely heavily on KOL partnerships, so it is critical to understand what motivates KOLs in order to establish meaningful partnerships.
 
• Understand that the goal of partnering is to ultimately lead to better medical outcomes
• Evaluate the partnership and how you can bring value to the KOL
• Build trust by staying aligned with KOL needs and goals
Register Now

This window is secured by 256 bit encryption on a PCI compliant network. Click here to view this window in its own page.

Subscribe to Conference Updates
Join our e-newsletter list to follow closely all news.
Event Sponsors
Event Partners
15
Speakers
21
Days
251
Participants
125
Workshops
90
Venue
Contact Us